Skip to main content
Premium Trial:

Request an Annual Quote

Celera Faces Shareholder Suit

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Celera today said that a shareholder suit filed against the firm and certain officers yesterday is without merit and it intends to "vigorously defend the action."

The Alameda, Calif.-based molecular diagnostics firm said that the lawsuit alleges that between April 24, 2008 and July 22, 2009, the company issued false and misleading statements about its business and financial results. The suit seeks unspecified damages on behalf of an alleged class of purchasers of the firm's stock during that period.

During the period specified in the lawsuit, Celera's shares fell 49 percent from its April 23, 2008 close of $15.15 to its July 22, 2009 close of $7.74. On April 24, 2008, Celera reported that its third-quarter revenues had increased four-fold, due primarily to two acquisitions during the previous year, while its net loss widened on a variety of charges to earnings.

A couple of months later, Celera completed its split from then-parent firm Applera.

At the end of the period cited in the lawsuit, Celera announced that it was implementing a restructuring plan in response to sagging revenues. The drop was due to lower sales from its Berkeley HeartLab business.

In early trade on the Nasdaq, shares of Celera were up just over 1 percent at $7.02.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.